Results 11 to 20 of about 25,204 (165)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma [PDF]

open access: yesESMO Open, 2021
Abstract Background: The incidence of oesophageal adenocarcinoma (OAC) is rapidly increasing and despite improvements in treatment, the five-year survival rate remains poor. Prognostic biomarkers that address the genomic heterogeneity in this highly complex disease will aid the development of precision therapeutics and improve patient survival.
Vanessa F. Bonazzi   +10 more
openaire   +4 more sources

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA

open access: yesCancer Biology & Medicine, 2021
Objective: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has been shown to produce an objective response in patients with pretreated mBC. Oral vinorelbine also holds promise as a treatment of choice in patients with mBC. This
Anjie Zhu   +19 more
doaj   +1 more source

The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy

open access: yesCancer Biology & Medicine, 2019
As immunotherapy has gained increasing interest as a new foundation for cancer therapy, some atypical response patterns, such as pseudoprogression and hyperprogression, have garnered the attention of physicians. Pseudoprogression is a phenomenon in which
Wenxiao Jia   +4 more
doaj   +1 more source

Minimally invasive differential diagnosis of melanocytic intraocular neoplasms

open access: yesРоссийский офтальмологический журнал, 2023
Purpose: to analyze the mutation frequency of the GNAQ/GNA11 gene in circulating tumor DNA and genotypes of the polymorphic marker C3435T of the ABCB1 gene in a large sample of patients with intraocular melanocytic neoplasms (IMN).Material and methods ...
A. Yu. Tsygankov   +4 more
doaj   +1 more source

Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements

open access: yesCells, 2019
In recent years, the introduction of new molecular techniques in experimental and clinical settings has allowed researchers and clinicians to propose circulating-tumor DNA (ctDNA) analysis and liquid biopsy as novel promising strategies for the early ...
Natalia O. Tuaeva   +12 more
doaj   +1 more source

ESR1 mutations in ER-positive breast cancer: from endocrine resistance to ctDNA-guided therapeutic interception [PDF]

open access: yesExploration of Targeted Anti-tumor Therapy
Endocrine resistance in estrogen receptor-positive (ER+) breast cancer has undergone a fundamental reconceptualization over the past decade. The discovery that activating mutations in the ESR1 gene encoding ERα emerge under aromatase inhibitor (AI ...
Thais Martinez   +2 more
doaj   +1 more source

Circulating Tumor Cells and ctDNA in Sarcomas

open access: yes, 2022
Sarcomas are clustered in two oncological entities named bone and soft-tissue sarcomas. Both are rare cancers originating from the mesenchyme, characterized by their propensity to induce the development of lung metastases. Sarcoma cells escaping from the primary tumor site, spread to the pulmonary tissue through the bloodstream where they found a ...
Heymann, Dominique   +4 more
openaire   +2 more sources

Impact of linker histone in the formation of ambochlorin-calf thymus DNA complex: Multi-spectroscopic, stopped-flow, and molecular modeling approaches [PDF]

open access: yesIranian Journal of Basic Medical Sciences, 2021
Objective(s): This study aimed to evaluate the role of the linker histone (H1) in the binding interaction between ambochlorin (Amb), and calf thymus DNA (ctDNA) as binary and ternary systems.
Azam Askari   +8 more
doaj   +1 more source

Status of liquid profiling in precision oncology – the need for integrative diagnostics for successful implementation into standard care

open access: yesJournal of Laboratory Medicine, 2022
The liquid profiling approach is currently at the threshold of translation from research application in various clinical trials to introduction into the management of cancer patients in the context of clinical care.
Froelich Matthias F.   +3 more
doaj   +1 more source

Survival of Lung Adenocarcinoma Patients with Tyrosine Kinase Inhibitor Therapy Based on EGFR Mutation Status in Tumor and Plasma Samples

open access: yesIndonesian Journal of Cancer, 2023
Background:The prognosis for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is greatly improved when treated with tyrosine kinase inhibitor (TKI).
Haryati Haryati   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy